Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
Naproxen Adjunct to Fluoxetine for Moderate-To-Severe Obsessive-Compulsive Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial Publisher Pubmed

Summary: Can naproxen ease OCD? Study finds naproxen with fluoxetine cuts obsession symptoms effectively. #OCD #Naproxen

Shamabadi A1 ; Motavalian Z1 ; Farahmand Y1 ; Farahmand K1 ; Arabzadeh Bahri R1 ; Askari S2 ; Ansari S3 ; Fallahzadeh M1 ; Shalbafan M2 ; Akhondzadeh S1
Authors

Source: Psychiatry and Clinical Neurosciences Published:2024


Abstract

Aim: Current treatments for obsessive-compulsive disorder (OCD) encounter resistance and limiting adverse events, necessitating novel therapeutic strategies. This study aimed to investigate the benefits of naproxen, a medication with effects on inflammation and neuronal function, on OCD. Methods: One hundred and four OCD outpatients with a Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) score of >21 were equally assigned to receive fluoxetine plus either naproxen 250 mg or matched placebo q12hr. Patients were assessed using the Y-BOCS by recording the subscale scores at baseline and weeks 5 and 10 to evaluate efficacy. They were also assessed in terms of tolerability. Results: Data from 96 patients were analyzed. The baseline characteristics were comparable between the groups. There were significant time-treatment interaction effects on the obsession subscale ((Formula presented.) = 0.055) and total ((Formula presented.) = 0.043) scores of Y-BOCS. Reductions in the obsession subscale and total scores of Y-BOCS were significantly greater in the fluoxetine plus naproxen group until the endpoint (Cohen's d = 0.560 and Cohen's d = 0.477, respectively). However, the difference in compulsion subscale score changes between the groups was not significant. Respondents with a reduction of ≥35% in Y-BOCS total scores were significantly more in the fluoxetine plus naproxen group (80.0% versus 47.8%). The side effect frequencies were comparable between the groups. Conclusion: Naproxen, adjunct to fluoxetine, outperformed adjunctive placebo in treating obsession and total symptoms of OCD patients in a safe and tolerable manner. Clinical trial registration: The study protocol was registered and published in the Iranian Registry of Clinical Trials (http://www.irct.ir; registration number IRCT20090117001556N139). © 2024 The Author(s). Psychiatry and Clinical Neurosciences © 2024 Japanese Society of Psychiatry and Neurology.
Related Docs
View other Related Docs
1. Amantadine As Adjuvant Therapy in the Treatment of Moderate to Severe Obsessive–Compulsive Disorder: A Double-Blind Randomized Trial With Placebo Control, Psychiatry and Clinical Neurosciences (2019)
2. Celecoxib As an Adjuvant to Fluvoxamine in Moderate to Severe Obsessive-Compulsive Disorder: A Double-Blind, Placebo-Controlled, Randomized Trial, Pharmacopsychiatry (2015)
3. Minocycline Combination Therapy With Fluvoxamine in Moderate-To-Severe Obsessive–Compulsive Disorder: A Placebo-Controlled, Double-Blind, Randomized Trial, Psychiatry and Clinical Neurosciences (2016)
Experts (# of related papers)
View all Related Experts
Shahin Akhondzadeh Basti (12)
Farzin Rezaei (3)
Naproxen Adjunct to Fluoxetine for Moderate-To-Severe Obsessive-Compulsive Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial
Other Related Docs
4. Riluzole in Augmentation of Fluvoxamine for Moderate to Severe Obsessive–Compulsive Disorder: Randomized, Double-Blind, Placebo-Controlled Study, Psychiatry and Clinical Neurosciences (2016)
5. L-Carnosine As an Adjuvant to Fluvoxamine in Treatment of Obsessive Compulsive Disorder: A Randomized Double-Blind Study, Human Psychopharmacology (2017)
6. Reboxetine Combination Therapy With Fluoxetine in Moderate to Severe Obsessive-Compulsive Disorder: A Placebo-Controlled, Double-Blind, Randomized Trial, Clinical Neuropharmacology (2023)
7. Fluvoxamine Combination Therapy With Tropisetron for Obsessive-Compulsive Disorder Patients: A Placebo-Controlled, Randomized Clinical Trial, Journal of Psychopharmacology (2019)
8. N-Acetylcysteine Augmentation Therapy for Moderate-To-Severe Obsessive-Compulsive Disorder: Randomized, Double-Blind, Placebo-Controlled Trial, Journal of Clinical Pharmacy and Therapeutics (2016)
9. Comparison of Saffron and Fluvoxamine in the Treatment of Mild to Moderate Obsessive-Compulsive Disorder: A Double Blind, Randomized Clinical Trial, Iranian Journal of Psychiatry (2017)
10. L-Theanine Combination Therapy With Fluvoxamine in Moderate-To-Severe Obsessive–Compulsive Disorder: A Placebo-Controlled, Double-Blind, Randomized Trial, Psychiatry and Clinical Neurosciences (2023)
11. 5-Hydroxytryptophan As Adjuvant Therapy in Treatment of Moderate to Severe Obsessive-Compulsive Disorder: A Double-Blind Randomized Trial With Placebo Control, International Clinical Psychopharmacology (2020)
12. Memantine Augmentation Improves Symptoms in Serotonin Reuptake Inhibitor-Refractory Obsessive-Compulsive Disorder: A Randomized Controlled Trial, Pharmacopsychiatry (2018)
13. Correlations Between Single Nucleotide Polymorphisms in Obsessive-Compulsive Disorder With the Clinical Features or Response to Therapy, Journal of Psychiatric Research (2023)
14. The Efficacy of Aripiprazole Versus Risperidone As Augmentation Therapy in Treatment-Resistant Obsessive-Compulsive Disorder: A Double Blind Clinical Trial, Iranian Red Crescent Medical Journal (2018)
15. A Systematic Review and Meta-Analysis: Memantine Augmentation in Moderate to Severe Obsessive-Compulsive Disorder, Psychiatry Research (2019)
16. The Safety and Efficacy of Transcranial Direct Current Stimulation As Add-On Therapy to Fluoxetine in Obsessive-Compulsive Disorder: A Randomized, Double-Blind, Sham-Controlled, Clinical Trial, BMC Psychiatry (2020)
17. A Comparative Study of Obsessive Beliefs in Obsessive-Compulsive Disorder, Anxiety Disorder Patients and a Normal Group, Acta Medica Iranica (2015)
18. Assessing the Effectiveness of Repetitive Transcranial Magnetic Stimulation in the Treatment of Obsessive- Compulsive Disorder, Clinical EEG and Neuroscience (2022)
19. Herbal Medicine in the Treatment of Obsessive Compulsive Disorder: A Review, Journal of Medicinal Plants (2019)
20. Glutamatergic Medications As Adjunctive Therapy for Moderate to Severe Obsessive-Compulsive Disorder in Adults: A Systematic Review and Meta-Analysis, BMC Pharmacology and Toxicology (2021)